System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jörg Henes is an expert in Rheumatology at Universitätsklinikum Tübingen (Germany). As of October 2026, ScienceLeadR ranks Jörg Henes in the top 1% of experts worldwide for Arthritis, Autoimmune Diseases and Scleroderma, Systemic. Jörg Henes has authored 435 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 7 of them ongoing. SLR score: 1,536 (community average: 125). How the SLR is computed.

LeadR Profile

Jörg Henes Universitätsklinikum Tübingen Germany
1 536 ScienceLeadR Reputation 1536

Unlock

Register Login
Network Map

Rheumatology

Subspecialties: Internal Medicine - Immunology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Universitätsklinikum Tübingen

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 435

Citations

Citations: 13 292 1st author: 45 Last author: 53 Unique author: 4

Main journals

Ann Rheum Dis 111
Z Rheumatol 43
Rheumatology (Oxford) 32
Clin Exp Rheumatol 14
Rheumatol Int 12

Best Journals

JAMA 2
Lancet Respir Med 1
Lancet Rheumatol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
CAR T-cell activity for autoimmune diseases across EBMT centers: an international survey on behalf of the Autoimmune Diseases Working Party and the Cellular Therapy and Immunobiology Working Party.
PMID 42876289 — cells, hematology, autoimmune diseases, therapeutics, t-lymphocytes, car-t cell		Haematologica20260
Proton pump inhibitor use and long-term outcomes in SSc: a real-life analysis from the EUSTAR database.
PMID 42760267 — mortality, phenotype, rheumatic diseases, proton pump inhibitors, proton pumps, lung diseases, interstitial		Rheumatology (Oxford)20260
Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study.
PMID 42758145 — sclerosis, hypertension, anticoagulants, hypertension, pulmonary, cohort studies, propensity score, rheumatic diseases, therapeutics, scleroderma, systemic		Rheumatology (Oxford)20260
Clinical and genetic characteristics of adult patients with familial Mediterranean fever at a German tertiary referral centre.
PMID 42665849 — pain, arthralgia, familial mediterranean fever, arthritis, therapeutics, mutation		BMC Rheumatol20260
Obinutuzumab in a patient with overlap syndrome of systemic sclerosis and myositis with perimyocarditis and renal crisis.
PMID 42635154 — sclerosis, myositis, scleroderma, systemic		Clin Exp Rheumatol20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 11
N/A 2
Phase 1/Phase 2 2
Phase 2 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 6
Recruiting 4
Active not recruiting 3
Unknown 3
Terminated 2
Not yet recruiting 1

By type:

Interventional 17
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 1
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 28

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
2023-504022-19-01 — dermatomyositis, muscular diseases, injections, safety, classification, myositis, polymyositis, therapeutics, injections, subcutaneous		Phase 3Not yet recruiting2024
Belimumab CTD ILD Long Term Extension Follow up to pivotal studies BLISSc ILD and BEconneCTD ILD
2023-509370-39-00 — sclerosis, lung, safety, connective tissue, connective tissue diseases, lung diseases, tissues, scleroderma, systemic, lung diseases, interstitial		Phase 3Recruiting2025
A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE)
2023-508191-11-00 — safety, lupus erythematosus, systemic		Phase 3Recruiting2024
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE 1)
2022-500699-76-00 — safety, lupus erythematosus, systemic		Phase 3Active not recruiting2023
MB CART19 1 in refractory SLE
2023-507654-33-00		Phase 1/Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS